Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.69 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.47 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.42 |
| ▸ | CDK1 | P06493 | 3/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.42 |
| ▸ | GSK3A | P49840 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 3/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996761 | 0.86 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL1993872 | 0.84 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL1992432 | 0.84 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL1994561 | 0.82 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL2886849 | 0.82 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL6640941 | 0.82 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MET | |
| SCHEMBL1994242 | 0.82 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MET | |
| SCHEMBL1998156 | 0.81 | MET (0.46) | MAPK14MAPK13MAPK12MAPK11CCNB2 | |
| SCHEMBL1996585 | 0.77 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL1993559 | 0.77 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11PRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2338890-A1 | 4,7-Diazaindole derivatives and their use as fungicides | Bayer CropScience AG (DE) | 2011-06-29 | — | — | EP | claimed |
| EP-2338890-A1 | 4,7-Diazaindole derivatives and their use as fungicides | Bayer CropScience AG (DE) | 2011-06-29 | — | — | EP | disclosed |
| EP-1025102-B1 | BICYCLIC KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2004-05-19 | — | — | EP | disclosed |
| US-6630485-B2 | For therapy of inflammatory disease | SYNTEX (U.S.A.) LLC | 2003-10-07 | — | — | US | disclosed |
| US-20030139462-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2003-07-24 | — | — | US | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020013354-A1 | p38 map kinase inhibitors | CHENG SOAN (US) | 2002-01-31 | — | — | US | disclosed |
| US-20010044538-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2001-11-22 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| CN-1279682-A | bicyclic kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2001-01-10 | — | — | CN | disclosed |
| EP-1025102-A1 | BICYCLIC KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020624-A1 | BICYCLIC KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013354-A1 | p38 map kinase inhibitors | MAPK1, MAPK8, MAP3K1 | MAPK14 31/4885MAPK13 33/4885MAPK12 35/4885 |
| US-20030139462-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | MAPK14 31/4885MAPK13 33/4885MAPK12 35/4885 |
| US-20010044538-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | MAPK14 31/4885MAPK13 33/4885MAPK12 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.